Mast Cell Activation Syndrome Update—A Dermatological Perspective
暂无分享,去创建一个
S. Georgescu | M. Tampa | C. Mitran | M. Mitran | Dana Mihele | Mihaela Tovaru | C. Condrat | Paul-Andrei Nistor | G. Bruma | D. Mihele
[1] A. Pardanani. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management , 2023, American journal of hematology.
[2] D. Hesselink,et al. The mast cell: A Janus in kidney transplants , 2023, Frontiers in Immunology.
[3] I. Kazama,et al. Cetirizine more potently exerts mast cell-stabilizing property than diphenhydramine. , 2022, Drug discoveries & therapeutics.
[4] M. Mogi,et al. Mast cells promote viral entry of SARS-CoV-2 via formation of chymase/spike protein complex , 2022, European Journal of Pharmacology.
[5] Ines Seitl,et al. Toward Oral Supplementation of Diamine Oxidase for the Treatment of Histamine Intolerance , 2022, Nutrients.
[6] M. Triggiani,et al. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022 , 2022, International Archives of Allergy and Immunology.
[7] M. Triggiani,et al. Global Classification of Mast Cell Activation Disorders An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. , 2022, The journal of allergy and clinical immunology. In practice.
[8] M. Maurer,et al. Idiopathic mast cell activation syndrome is more often suspected than diagnosed—A prospective real‐life study , 2022, Allergy.
[9] Yanqin Yu,et al. Luteolin inhibits FcεRΙ‐ and MRGPRX2‐mediated mast cell activation by regulating calcium signaling pathways , 2022, Phytotherapy research : PTR.
[10] Bradford A. Youngblood,et al. Mast cell activation is associated with post‐acute COVID‐19 syndrome , 2021, Allergy.
[11] S. Gangemi,et al. Basophils and Mast Cells in COVID-19 Pathogenesis , 2021, Cells.
[12] D. Pattanaik,et al. Mastocytosis and Mast Cell Activation Disorders: Clearing the Air , 2021, International journal of molecular sciences.
[13] A. Walters,et al. Mast cell activation symptoms are prevalent in Long-COVID , 2021, International Journal of Infectious Diseases.
[14] A. Kopylov,et al. Food Intolerance: The Role of Histamine , 2021, Nutrients.
[15] M. Wawruch,et al. Histamine Intolerance—The More We Know the Less We Know. A Review , 2021, Nutrients.
[16] G. Nilsson,et al. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. , 2021, The journal of allergy and clinical immunology. In practice.
[17] S. Yong. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments , 2021, Infectious diseases.
[18] M. Haffner-Luntzer,et al. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. , 2021, Seminars in cell & developmental biology.
[19] J. Lyons,et al. Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis , 2021, Current Allergy and Asthma Reports.
[20] J. Lyons,et al. The genetic basis and clinical impact of hereditary alpha-tryptasemia. , 2021, The journal of allergy and clinical immunology. In practice.
[21] A. Bayat,et al. A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis , 2020, International journal of molecular sciences.
[22] M. Triggiani,et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine , 2020, International journal of molecular sciences.
[23] C. Di Raimondo,et al. Cutaneous mastocytosis: A dermatological perspective , 2020, The Australasian journal of dermatology.
[24] P. Conti,et al. COVID-19 and Multisystem Inflammatory Syndrome, or is it mast cell activation syndrome? , 2020, Journal of biological regulators and homeostatic agents.
[25] L. Weinstock,et al. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome , 2020, International Journal of Infectious Diseases.
[26] M. T. Veciana-Nogués,et al. Histamine Intolerance: The Current State of the Art , 2020, Biomolecules.
[27] P. Korošec,et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. , 2020, The Journal of allergy and clinical immunology.
[28] Sarit Pal,et al. Emerging Roles of Mast Cells in the Regulation of Lymphatic Immuno-Physiology , 2020, Frontiers in Immunology.
[29] L. Weinstock,et al. Mast Cell Activation Syndrome: A Primer for the Gastroenterologist , 2020, Digestive Diseases and Sciences.
[30] M. Yokosuka,et al. Expressions of vascular endothelial growth factor receptors, Flk1 and Flt1, in rat skin mast cells during development , 2020, The Journal of veterinary medical science.
[31] Sage T. Hellerstedt,et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis , 2020 .
[32] C. Weiler. MCAS: Tools for Diagnosis and Differential Diagnosis. , 2020, The journal of allergy and clinical immunology. In practice.
[33] Sage T. Hellerstedt,et al. Anaphylaxis - a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis. , 2020, The Journal of allergy and clinical immunology.
[34] G. Hildebrandt,et al. Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease , 2019, Front. Immunol..
[35] R. Jessberger,et al. Regulation of the pleiotropic effects of tissue-resident mast cells. , 2019, The Journal of allergy and clinical immunology.
[36] J. Bernstein,et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast Cell Activation Syndrome (MCAS) Diagnosis and Management. , 2019, The Journal of allergy and clinical immunology.
[37] T. Biedermann,et al. Mast cells as protectors of health. , 2019, The Journal of allergy and clinical immunology.
[38] S. Galli,et al. Mast cells are critical for controlling the bacterial burden and the healing of infected wounds , 2019, Proceedings of the National Academy of Sciences.
[39] P. Dubreuil,et al. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. , 2019, The journal of allergy and clinical immunology. In practice.
[40] A. Bayat,et al. A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin. , 2019, The Journal of investigative dermatology.
[41] Christopher Chang,et al. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS) , 2019, Clinical Reviews in Allergy & Immunology.
[42] F. Granata,et al. Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019 , 2019, International Archives of Allergy and Immunology.
[43] B. Schraven,et al. Engulfment of mast cell secretory granules on skin inflammation boosts dendritic cell migration and priming efficiency , 2019, The Journal of allergy and clinical immunology.
[44] A. Di Nardo,et al. Lipocalin 2: A New Antimicrobial in Mast Cells , 2019, International journal of molecular sciences.
[45] Christopher Chang,et al. A review of the evidence for the existence of and relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS) , 2019, The Journal of Immunology.
[46] T. Theoharides,et al. Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders? , 2019, Expert review of clinical immunology.
[47] M. Triggiani,et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. , 2019, The journal of allergy and clinical immunology. In practice.
[48] J. Butterfield,et al. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. , 2019, The journal of allergy and clinical immunology. In practice.
[49] A. Soulika,et al. The Dynamics of the Skin’s Immune System , 2019, International journal of molecular sciences.
[50] S. Woo,et al. Dexamethasone Promotes Keratinocyte Proliferation by Triggering Keratinocyte Growth Factor in Mast Cells , 2019, International Archives of Allergy and Immunology.
[51] P. S. Santa Maria,et al. A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms , 2019, Clinical Reviews in Allergy & Immunology.
[52] L. Wise,et al. The Cutaneous Inflammatory Response to Thermal Burn Injury in a Murine Model , 2019, International journal of molecular sciences.
[53] P. Hollingsworth,et al. Successful treatment of idiopathic mast cell activation syndrome with low‐dose Omalizumab , 2019, Clinical & translational immunology.
[54] A. Fedorowski. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management , 2018, Journal of internal medicine.
[55] S. D. de Feraudy,et al. Diffuse cutaneous mastocytosis: Case report and literature review , 2018, Pediatric dermatology.
[56] A. Clark,et al. Diagnostic Value of Tryptase in Food Allergic Reactions: A Prospective Study of 160 Adult Peanut Challenges. , 2018, The journal of allergy and clinical immunology. In practice.
[57] C. Mathias,et al. The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets , 2018, Front. Immunol..
[58] M. Hamilton. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. , 2018, Immunology and allergy clinics of North America.
[59] D. Fatovich,et al. Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia , 2018, Emergency medicine Australasia : EMA.
[60] C. Bernardi,et al. Histamine food poisonings: A systematic review and meta-analysis , 2018, Critical reviews in food science and nutrition.
[61] P. Bradding,et al. The controversial role of mast cells in fibrosis , 2018, Immunological reviews.
[62] L. Romani,et al. The contribution of mast cells to bacterial and fungal infection immunity , 2018, Immunological reviews.
[63] B. Schröder,et al. Mast cells acquire MHCII from dendritic cells during skin inflammation , 2017, The Journal of experimental medicine.
[64] L. Biesecker,et al. A common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number , 2017, Genetics in Medicine.
[65] R. Fox,et al. Successful targeted treatment of mast cell activation syndrome with tofacitinib , 2017, European journal of haematology.
[66] C. Schäfer,et al. Leitlinie zum Vorgehen bei Verdacht auf Unverträglichkeit gegenüber oral aufgenommenem Histamin , 2017, Allergo Journal.
[67] S. Seneviratne,et al. Mast cell disorders in Ehlers–Danlos syndrome , 2017, American journal of medical genetics. Part C, Seminars in medical genetics.
[68] A. Thomsen,et al. The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung , 2017, Oncotarget.
[69] J. Gui,et al. Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases , 2017, Scientific Reports.
[70] J. Menk,et al. Characterization of Mast Cell Activation Syndrome , 2016, The American journal of the medical sciences.
[71] Tang Jian,et al. The Role of the Mast Cell in Skin Aging , 2016 .
[72] G. Ogg,et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a , 2016, The Journal of experimental medicine.
[73] Andrew J. Oler,et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number , 2016, Nature Genetics.
[74] D. Staines,et al. Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. , 2016, Asian Pacific journal of allergy and immunology.
[75] M. Tsai,et al. IgE and mast cells in host defense against parasites and venoms , 2016, Seminars in Immunopathology.
[76] J. Mlček,et al. Quercetin and Its Anti-Allergic Immune Response , 2016, Molecules.
[77] S. Holdsworth,et al. Mast Cell Stabilization Ameliorates Autoimmune Anti-Myeloperoxidase Glomerulonephritis. , 2016, Journal of the American Society of Nephrology : JASN.
[78] Gregorio Gomez,et al. Resveratrol preferentially inhibits IgE-dependent PGD2 biosynthesis but enhances TNF production from human skin mast cells. , 2016, Biochimica et biophysica acta.
[79] M. Di Gioacchino,et al. Serum diamine oxidase activity in patients with histamine intolerance , 2016, International journal of immunopathology and pharmacology.
[80] S. Galli. The Mast Cell-IgE Paradox: From Homeostasis to Anaphylaxis. , 2016, The American journal of pathology.
[81] L. Afrin,et al. Successful treatment of mast cell activation syndrome with sunitinib , 2015, European journal of haematology.
[82] Amanda Carroll-Portillo,et al. Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation , 2015, The Journal of cell biology.
[83] R. Bissonnette,et al. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. , 2015, The Journal of allergy and clinical immunology.
[84] P. Quax,et al. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. , 2015, Atherosclerosis.
[85] Theoharis C. Theoharides,et al. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin , 2015, Front. Neurosci..
[86] H. Taute,et al. Premature Collagen Fibril Formation, Fibroblast-Mast Cell Interactions and Mast Cell-Mediated Phagocytosis of Collagen in Keloids , 2015, Ultrastructural pathology.
[87] G. Mortier,et al. Familial hypertryptasemia with associated mast cell activation syndrome. , 2014, The Journal of allergy and clinical immunology.
[88] T. Moon,et al. Mast Cell Mediators: Their Differential Release and the Secretory Pathways Involved , 2014, Front. Immunol..
[89] U. Bertheim,et al. The structure of the basement membrane zone differs between keloids, hypertrophic scars and normal skin: a possible background to an impaired function. , 2014, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[90] Xinzhong Dong,et al. Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.
[91] D. Mathis,et al. Type 1 Diabetes in NOD Mice Unaffected by Mast Cell Deficiency , 2014, Diabetes.
[92] K. Jensen,et al. Prostaglandin D2-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study , 2014, Journal of Translational Medicine.
[93] J. Malinovsky,et al. Diagnostic Value of Histamine and Tryptase Concentrations in Severe Anaphylaxis with Shock or Cardiac Arrest during Anesthesia , 2014, Anesthesiology.
[94] G. Pejler,et al. Mast cell secretory granules: armed for battle , 2014, Nature Reviews Immunology.
[95] L. DiPietro,et al. Blockade of Mast Cell Activation Reduces Cutaneous Scar Formation , 2014, PloS one.
[96] K. Sokol,et al. Ketotifen in the management of chronic urticaria: resurrection of an old drug. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[97] S. Galli,et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. , 2013, Blood.
[98] M. Tsai,et al. A beneficial role for immunoglobulin E in host defense against honeybee venom. , 2013, Immunity.
[99] S. Tenzer,et al. Mast cell-derived mediators promote murine neutrophil effector functions. , 2013, International immunology.
[100] O. Olutoye,et al. Equine exuberant granulation tissue and human keloids: a comparative histopathologic study. , 2013, Veterinary surgery : VS.
[101] M. Nöthen,et al. Familial Occurrence of Systemic Mast Cell Activation Disease , 2013, PloS one.
[102] M. Maeda-Yamamoto. Human clinical studies of tea polyphenols in allergy or life style-related diseases. , 2013, Current pharmaceutical design.
[103] C. Akin,et al. Mastocytosis: update on pharmacotherapy and future directions , 2013, Expert opinion on pharmacotherapy.
[104] A. Lægreid,et al. Platelet-activating factor induces proliferation in differentiated keratinocytes , 2013, Molecular and Cellular Biochemistry.
[105] P. Valent,et al. Mast cell activation syndromes: definition and classification , 2013, Allergy.
[106] T. Honda,et al. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. , 2013, The Journal of investigative dermatology.
[107] M. Mildner,et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model , 2012, Allergy.
[108] A. Bayat,et al. Site‐specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates , 2012, The British journal of dermatology.
[109] S. Hartmann,et al. Regulation of type 2 immunity to helminths by mast cells , 2012, Gut microbes.
[110] F. Levi-Schaffer,et al. Novel Identified Receptors on Mast Cells , 2012, Front. Immun..
[111] K. Austen,et al. Developmental origin and functional specialization of mast cell subsets. , 2012, Immunity.
[112] C. Pucillo,et al. Mast Cell: An Emerging Partner in Immune Interaction , 2012, Front. Immun..
[113] M. Ikeda,et al. First and second generation H₁ histamine receptor antagonists produce different sleep-inducing profiles in rats. , 2012, European journal of pharmacology.
[114] L. Afrin. Sclerosing mediastinitis and mast cell activation syndrome. , 2012, Pathology, research and practice.
[115] K. Mönkemüller,et al. Mast cell activation syndrome (MCAS) diagnosed using double-balloon enteroscopy , 2012, Endoscopy.
[116] B. Igyártó,et al. Early immune events in the induction of allergic contact dermatitis , 2012, Nature Reviews Immunology.
[117] M. Triggiani,et al. Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal , 2011, International Archives of Allergy and Immunology.
[118] Susan M. Schlenner,et al. Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. , 2011, The Journal of clinical investigation.
[119] A. Bruce,et al. Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis , 2011, The Journal of Immunology.
[120] A. Waisman,et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. , 2011, Immunity.
[121] M. Rohde,et al. Staphylococcus aureus Evades the Extracellular Antimicrobial Activity of Mast Cells by Promoting Its Own Uptake , 2011, Journal of Innate Immunity.
[122] J. Lamb,et al. Mast cells in health and disease. , 2011, Clinical science.
[123] L. Afrin. Burning mouth syndrome and mast cell activation disorder. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[124] D. Bentrem,et al. The significant role of mast cells in cancer , 2011, Cancer and Metastasis Reviews.
[125] P. Valent,et al. Mast cell activation syndrome: Proposed diagnostic criteria. , 2010, The Journal of allergy and clinical immunology.
[126] Gunnar Pejler,et al. Mast cell proteases: multifaceted regulators of inflammatory disease. , 2010, Blood.
[127] S. Abraham,et al. Mast cell-orchestrated immunity to pathogens , 2010, Nature Reviews Immunology.
[128] Erika Peterson,et al. IL-33 augments substance P–induced VEGF secretion from human mast cells and is increased in psoriatic skin , 2010, Proceedings of the National Academy of Sciences.
[129] R. Liblau,et al. Cell-cell cooperation at the T helper cell/mast cell immunological synapse. , 2009, Blood.
[130] P. Kwok,et al. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. , 2009, The Journal of allergy and clinical immunology.
[131] M. Maurer,et al. Desloratadine inhibits human skin mast cell activation and histamine release. , 2009, The Journal of investigative dermatology.
[132] M. Løvik,et al. The Role of Natural Killer Cells in Resistance to the Intracellular Bacterium Listeria monocytogenes in Rats , 2009, Scandinavian journal of immunology.
[133] M. Eichner,et al. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. , 2009, Blood.
[134] B. Ryffel,et al. TLR2-dependent mast cell activation contributes to the control of Mycobacterium tuberculosis infection. , 2009, Microbes and infection.
[135] M. Triggiani,et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. , 2009, The Journal of allergy and clinical immunology.
[136] John T. Chang,et al. Inducible MHC Class II Expression by Mast Cells Supports Effector and Regulatory T Cell Activation 1 , 2009, The Journal of Immunology.
[137] S. Holdsworth,et al. Role of mast cells in progressive renal diseases. , 2008, Journal of the American Society of Nephrology : JASN.
[138] P. Wolters,et al. Mast Cell IL-6 Improves Survival from Klebsiella Pneumonia and Sepsis by Enhancing Neutrophil Killing1 , 2008, The Journal of Immunology.
[139] J. Butterfield,et al. Prevention of Mast Cell Activation Disorder-Associated Clinical Sequelae of Excessive Prostaglandin D2 Production , 2008, International Archives of Allergy and Immunology.
[140] M. Tsai,et al. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity , 2008, Nature Reviews Immunology.
[141] A. Di Nardo,et al. Mast Cell Cathelicidin Antimicrobial Peptide Prevents Invasive Group A Streptococcus Infection of the Skin1 , 2008, The Journal of Immunology.
[142] Manfred Rohde,et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. , 2008, Blood.
[143] B. Sutton,et al. IgE in allergy and asthma today , 2008, Nature Reviews Immunology.
[144] D. Hart,et al. The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[145] G. Liss,et al. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. , 2008, The Journal of allergy and clinical immunology.
[146] Susan M. Schlenner,et al. Molecular mechanism of mast cell–mediated innate defense against endothelin and snake venom sarafotoxin , 2007, The Journal of experimental medicine.
[147] G. Caughey. Mast cell tryptases and chymases in inflammation and host defense , 2007, Immunological reviews.
[148] M. Brüss,et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder , 2007, Scandinavian journal of gastroenterology.
[149] C. Bachert,et al. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. , 2006, Respiratory medicine.
[150] C. Chen,et al. Mast Cells Can Enhance Resistance to Snake and Honeybee Venoms , 2006, Science.
[151] J. D. den Hollander,et al. Mast cell distribution in normal adult skin , 2005, Journal of Clinical Pathology.
[152] M. Tsai,et al. Mast cells in the development of adaptive immune responses , 2005, Nature Immunology.
[153] J. Marshall. Mast-cell responses to pathogens , 2004, Nature Reviews Immunology.
[154] P. Gutiérrez-Castrellón,et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.
[155] D. Santini,et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.
[156] A. D. Rodrigues,et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[157] S. Inan,et al. The roles of Transforming growth Factor Type β3(TGF-β3) and mast cells in the pathogenesis of scleroderma , 2003, Clinical Rheumatology.
[158] C. Ra,et al. T Cells and Mast Cells as a Major Source of Interleukin-13 in Atopic Dermatitis , 2002, Dermatology.
[159] Marek Jutel,et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors , 2001, Nature.
[160] G. Nilsson,et al. Inhibition of keratinocyte growth in cell culture and whole skin culture by mast cell mediators , 2001, Experimental dermatology.
[161] T. Zuberbier,et al. Expression of mast cell growth modulating and chemotactic factors and their receptors in human cutaneous scars. , 2001, The Journal of investigative dermatology.
[162] M. Rogers,et al. Presentation of cutaneous mastocytosis in 173 children , 2001, The Australasian journal of dermatology.
[163] A. Namane,et al. Mast Cell-Dependent B and T Lymphocyte Activation Is Mediated by the Secretion of Immunologically Active Exosomes1 , 2001, The Journal of Immunology.
[164] G. Kollias,et al. Mast Cells Control Neutrophil Recruitment during T Cell–Mediated Delayed-Type Hypersensitivity Reactions through Tumor Necrosis Factor and Macrophage Inflammatory Protein 2 , 2000, The Journal of experimental medicine.
[165] D. Friend,et al. Senescent Jejunal Mast Cells and Eosinophils in the Mouse Preferentially Translocate to the Spleen and Draining Lymph Node, Respectively, During the Recovery Phase of Helminth Infection1 , 2000, The Journal of Immunology.
[166] E. Bröcker,et al. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein‐1 is correlated with recruitment of mast cells which synthesize interleukin‐4 in vivo , 2000, The Journal of pathology.
[167] D. Woolley,et al. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion , 1999, Arthritis research.
[168] S. Durham,et al. IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. , 1998, The Journal of allergy and clinical immunology.
[169] S. Abraham,et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α , 1996, Nature.
[170] A. Naukkarinen,et al. Mast cells are one major source of interleukin‐4 in atopic dermatitis , 1994, The British journal of dermatology.
[171] S. Abraham,et al. Mast cell phagocytosis of FimH-expressing enterobacteria. , 1994, Journal of immunology.
[172] C. Armstrong,et al. The skin as an immune organ. , 1994, The Western journal of medicine.
[173] Y. Okayama,et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[174] M. Profet. The Function of Allergy: Immunological Defense Against Toxins , 1991, The Quarterly Review of Biology.
[175] W. Eaglstein,et al. Exogenous electric current can reduce the formation of hypertrophic scars. , 1989, The Journal of dermatologic surgery and oncology.
[176] C. J. Smith,et al. The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. , 1987, The Journal of burn care & rehabilitation.
[177] L. Schwartz,et al. Mast cells in human keloid, small intestine, and lung by an immunoperoxidase technique using a murine monoclonal antibody against tryptase. , 1986, The American journal of pathology.
[178] L. Schwartz,et al. Two types of human mast cells that have distinct neutral protease compositions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[179] I. K. Cohen,et al. Histamine and collagen synthesis in keloid and hypertrophic scar. , 1973, Surgical forum.
[180] M. Tsai,et al. Mast Cells and IgE can Enhance Survival During Innate and Acquired Host Responses to Venoms. , 2017, Transactions of the American Clinical and Climatological Association.
[181] M. Tsai,et al. IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity. , 2016, The Journal of allergy and clinical immunology.
[182] F. Dumoulin,et al. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases , 2015, Brain, Behavior, and Immunity.
[183] D. Orgill,et al. Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing. , 2014, Advances in immunology.
[184] P. Valent,et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. , 2013, The journal of allergy and clinical immunology. In practice.
[185] L. Afrin. Mast cell activation syndrome masquerading as agranulocytosis. , 2012, Military medicine.
[186] L. Afrin,et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. , 2011, Journal of hematology & oncology.
[187] W. Aberer,et al. Histamine intolerance: lack of reproducibility of single symptoms by oral provocation with histamine: A randomised, double-blind, placebo-controlled cross-over study , 2010, Wiener klinische Wochenschrift.
[188] G. Barbara,et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.
[189] K. Takeda,et al. Increased number of mast cells accompany enhanced collagen synthesis in linear localized scleroderma , 2004, Archives of Dermatological Research.
[190] S. Toda,et al. Mast cells and angiogenesis , 2003, Microscopy research and technique.
[191] L. Hültner,et al. Classical and alternative pathways of mast cell activation. , 2002, Critical reviews in immunology.
[192] P. Welker,et al. Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue. , 2000, The Journal of investigative dermatology.